Arrigo F G Cicero
Arrigo F G Cicero is an expert in Cardiology at Policlinico S.Orsola-Malpighi (Italy). As of October 2026, ScienceLeadR ranks Arrigo F G Cicero in the top 1% of experts worldwide for Hypercholesterolemia, Dyslipidemias and Metabolic Syndrome. Arrigo F G Cicero has authored 715 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 12 of them ongoing. SLR score: 2,645 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Nutrition - Biochemistry - Endocrinology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 715
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Pathophysiology of aldosterone dysregulation in difficult-to-control hypertension. PMID 42847229 — hyperkalemia, hypertension, aldosterone, blood, heart failure, blood pressure, phenotype, hyperaldosteronism, receptors, mineralocorticoid, therapeutics | Am J Hypertens | 2026 | 0 |
| Global, regional, and national burden of tetanus in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. PMID 42840379 — mortality, vaccines, incidence, income, global burden of disease, prevalence, sex, cost of illness, demography, tetanus | EClinicalMedicine | 2026 | 0 |
| Lifestyle strategies and nutraceuticals in chronic venous disease: an evidence-weighted synthesis and clinical positioning. PMID 42828782 — quality of life, life style, phenotype, ulcer, adiposity, diet, parenteral nutrition, flavonoids, enteral nutrition, weight control | Clin Nutr | 2026 | 0 |
| Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. PMID 42814432 — heart diseases, heart failure, heart, cardiovascular diseases, public health, global burden of disease, prevalence, cost of illness, chagas disease | JAMA Cardiol | 2026 | 0 |
| Chemerin and Arterial Stiffness in the Brisighella Heart Study: A Residual-Based Discordance Analysis. PMID 42794691 — heart, classification, adipokines | Int J Mol Sci | 2026 | 0 |
Clinical Studies 22
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An open label extension (OLE) trial to evaluate long term safety and tolerability of pelacarsen (TQJ230) 2024-519870-38-00 — safety, cardiovascular diseases | Phase 3 | Not yet recruiting | 2026 |
| HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity 2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research | Phase 3 | Recruiting | 2026 |
| Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk 2025-524265-24-00 — dyslipidemias, therapeutics, lipids | Phase 3 | Recruiting | 2026 |
| A Trial to Test How AZD0780 Affects Serious Heart Stroke or Vascular Problems in Patients with Heart Stroke or Vascular Disease or at High Risk for Such Issues 2025-520519-14-00 — stroke, heart, cardiovascular diseases, vascular diseases | Phase 3 | Recruiting | 2025 |
| Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals NCT07515573 — coenzymes, docosahexaenoic acids, fatty acids, omega-3, vitamins, vitamin e, dyslipidemias, dietary supplements, fish oils, fruit, capsules, cholesterol, folic acid, cholesterol, hdl, eicosapentaenoic acid, taste, fatty acids, lipids | N/A | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map